capsazepine  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Alomone Labs capsazepine
    Acid-induced prolonged antinociceptive signaling in muscle. The withdrawal responses of mouse hind paws to a 0.2-mN bending force in mice before and after intramuscular acid injection in the gastrocnemius muscle. (A) In the dual acid injection scheme, mice showed transient hyperalgesia after the first intramuscular acid injection and chronic hyperalgesia after a second acid injection spaced 5 days apart. (B) A mix of acid saline with APETx2 and <t>capsazepine</t> abolished the transient hyperalgesia with the first injection and prevented the development of chronic hyperalgesia induced by the second acid injection 5 days later. (C,D) With the first acid injection, acid induced a prolonged antinociceptive effect lasting for 2 days, with ASIC3 and TRPV1 blocked by APETx2 and capsazepine, respectively, and a second acid injection at day 2 could not induce any hyperalgesic effect. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine. *P < 0.05 compared with the response at baseline.
    Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    capsazepine - by Bioz Stars, 2023-03
    86/100 stars

    Images

    1) Product Images from "Acid mediates a prolonged antinociception via substance P signaling in acid-induced chronic widespread pain"

    Article Title: Acid mediates a prolonged antinociception via substance P signaling in acid-induced chronic widespread pain

    Journal: Molecular Pain

    doi: 10.1186/1744-8069-10-30

    Acid-induced prolonged antinociceptive signaling in muscle. The withdrawal responses of mouse hind paws to a 0.2-mN bending force in mice before and after intramuscular acid injection in the gastrocnemius muscle. (A) In the dual acid injection scheme, mice showed transient hyperalgesia after the first intramuscular acid injection and chronic hyperalgesia after a second acid injection spaced 5 days apart. (B) A mix of acid saline with APETx2 and capsazepine abolished the transient hyperalgesia with the first injection and prevented the development of chronic hyperalgesia induced by the second acid injection 5 days later. (C,D) With the first acid injection, acid induced a prolonged antinociceptive effect lasting for 2 days, with ASIC3 and TRPV1 blocked by APETx2 and capsazepine, respectively, and a second acid injection at day 2 could not induce any hyperalgesic effect. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine. *P < 0.05 compared with the response at baseline.
    Figure Legend Snippet: Acid-induced prolonged antinociceptive signaling in muscle. The withdrawal responses of mouse hind paws to a 0.2-mN bending force in mice before and after intramuscular acid injection in the gastrocnemius muscle. (A) In the dual acid injection scheme, mice showed transient hyperalgesia after the first intramuscular acid injection and chronic hyperalgesia after a second acid injection spaced 5 days apart. (B) A mix of acid saline with APETx2 and capsazepine abolished the transient hyperalgesia with the first injection and prevented the development of chronic hyperalgesia induced by the second acid injection 5 days later. (C,D) With the first acid injection, acid induced a prolonged antinociceptive effect lasting for 2 days, with ASIC3 and TRPV1 blocked by APETx2 and capsazepine, respectively, and a second acid injection at day 2 could not induce any hyperalgesic effect. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine. *P < 0.05 compared with the response at baseline.

    Techniques Used: Injection

    Substance P mediates the acid-induced prolonged antinociception in acid-induced chronic widespread pain model. (A,B) APETx2 and capsazepine prevented acid-induced chronic hyperalgesia in tachykinin 1-positive ( Tac1 +/+ ) mice (A) but not Tac1 −/− mice (B) when the second acid injection was given the next day. (C) Pretreatment with pH 7.4 saline did not affect the acid-induced hyperalgesia in wild-type mice. (D) Pretreatment with SM-SP abolished the acid-induced transient hyperalgesia the next day and prevented the development of chronic hyperalgesia induced by a second acid injection 5 days later. (E) Pretreatment with SM-SP 5 days before the acid injection did not affect the acid-induced transient and chronic hyperalgesia in the dual acid injection scheme. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. Green arrow indicates when mice received a pretreatment of pH 7.4 saline 1 day before the acid injection. Blue arrows indicate when mice received a pretreatment of SM-SP 1 or 5 days before acid injection. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine; SM-SP, [Sar 9 ,Met(O 2 ) 11 ]-substance P; Tac1, tachykinin 1. *P < 0.05 compared with the response at baseline.
    Figure Legend Snippet: Substance P mediates the acid-induced prolonged antinociception in acid-induced chronic widespread pain model. (A,B) APETx2 and capsazepine prevented acid-induced chronic hyperalgesia in tachykinin 1-positive ( Tac1 +/+ ) mice (A) but not Tac1 −/− mice (B) when the second acid injection was given the next day. (C) Pretreatment with pH 7.4 saline did not affect the acid-induced hyperalgesia in wild-type mice. (D) Pretreatment with SM-SP abolished the acid-induced transient hyperalgesia the next day and prevented the development of chronic hyperalgesia induced by a second acid injection 5 days later. (E) Pretreatment with SM-SP 5 days before the acid injection did not affect the acid-induced transient and chronic hyperalgesia in the dual acid injection scheme. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. Green arrow indicates when mice received a pretreatment of pH 7.4 saline 1 day before the acid injection. Blue arrows indicate when mice received a pretreatment of SM-SP 1 or 5 days before acid injection. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine; SM-SP, [Sar 9 ,Met(O 2 ) 11 ]-substance P; Tac1, tachykinin 1. *P < 0.05 compared with the response at baseline.

    Techniques Used: Injection

    capsazepine  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Alomone Labs capsazepine
    Quantification of cystine acquisition in MDA-MB-231 cells in the presence of <t>capsazepine</t> (CPZ). Notes: CPZ inhibits the uptake of 14 C-cystine when incubated with 0–50 μM of the compound. This effect is comparable to intracellular levels of 14 C-cystine after incubation with sulfasalazine, a known system x c − inhibitor. Data are expressed as the fold change in counts per minute/mg protein (±standard error of the mean) relative to vehicle control (dimethyl sulfoxide). ** P <0.01; *** P <0.001; **** P <0.0001.
    Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    capsazepine - by Bioz Stars, 2023-03
    86/100 stars

    Images

    1) Product Images from "Identification of capsazepine as a novel inhibitor of system x c − and cancer-induced bone pain"

    Article Title: Identification of capsazepine as a novel inhibitor of system x c − and cancer-induced bone pain

    Journal: Journal of Pain Research

    doi: 10.2147/JPR.S125045

    Quantification of cystine acquisition in MDA-MB-231 cells in the presence of capsazepine (CPZ). Notes: CPZ inhibits the uptake of 14 C-cystine when incubated with 0–50 μM of the compound. This effect is comparable to intracellular levels of 14 C-cystine after incubation with sulfasalazine, a known system x c − inhibitor. Data are expressed as the fold change in counts per minute/mg protein (±standard error of the mean) relative to vehicle control (dimethyl sulfoxide). ** P <0.01; *** P <0.001; **** P <0.0001.
    Figure Legend Snippet: Quantification of cystine acquisition in MDA-MB-231 cells in the presence of capsazepine (CPZ). Notes: CPZ inhibits the uptake of 14 C-cystine when incubated with 0–50 μM of the compound. This effect is comparable to intracellular levels of 14 C-cystine after incubation with sulfasalazine, a known system x c − inhibitor. Data are expressed as the fold change in counts per minute/mg protein (±standard error of the mean) relative to vehicle control (dimethyl sulfoxide). ** P <0.01; *** P <0.001; **** P <0.0001.

    Techniques Used: Incubation

    Capsazepine treatment induces the production of reactive oxygen species. Notes: Quantification of intracellular levels of reactive oxygen species (ROS) as measured by DCFDA over 24 and 48 hours of treatment with capsazepine (CPZ) and 5′-iodoresiniferatoxin (IRTX; A ). After 48 hours, 25 μM of CPZ induces a significant increase in ROS relative to dimethyl sulfoxide-treated cells ( P <0.001). Treatment with IRTX does not result in significant changes in ROS over this time course. These data are represented as mean fold change ±standard error of mean relative to vehicle-treated cells. One-way analysis of variance (ANOVA) was used to measure significant increases in ROS relative to vehicle-treated control. CPZ-induced ROS production is abolished by co-treatment with 5 mM N-acetyl cysteine (NAC; B ). An unpaired t -test was used to assess significance of NAC addition at each time point. Cell survival decreases in a dose-dependent manner after treatment for 48 hours with CPZ. Co-treatment with 5 mM NAC increases cell survival relative to treatment with CPZ alone ( C ). Cell survival at 100 μM CPZ is significantly higher in the presence of 5 mM NAC ( P <0.001; one-way ANOVA comparing each concentration of CPZ without NAC to those with the addition of NAC). * P <0.05; ** P <0.01; *** P <0.001. Abbreviations: DCFDA, dichlorofluorescein diacetate derivative; RFU, relative fluorescent units.
    Figure Legend Snippet: Capsazepine treatment induces the production of reactive oxygen species. Notes: Quantification of intracellular levels of reactive oxygen species (ROS) as measured by DCFDA over 24 and 48 hours of treatment with capsazepine (CPZ) and 5′-iodoresiniferatoxin (IRTX; A ). After 48 hours, 25 μM of CPZ induces a significant increase in ROS relative to dimethyl sulfoxide-treated cells ( P <0.001). Treatment with IRTX does not result in significant changes in ROS over this time course. These data are represented as mean fold change ±standard error of mean relative to vehicle-treated cells. One-way analysis of variance (ANOVA) was used to measure significant increases in ROS relative to vehicle-treated control. CPZ-induced ROS production is abolished by co-treatment with 5 mM N-acetyl cysteine (NAC; B ). An unpaired t -test was used to assess significance of NAC addition at each time point. Cell survival decreases in a dose-dependent manner after treatment for 48 hours with CPZ. Co-treatment with 5 mM NAC increases cell survival relative to treatment with CPZ alone ( C ). Cell survival at 100 μM CPZ is significantly higher in the presence of 5 mM NAC ( P <0.001; one-way ANOVA comparing each concentration of CPZ without NAC to those with the addition of NAC). * P <0.05; ** P <0.01; *** P <0.001. Abbreviations: DCFDA, dichlorofluorescein diacetate derivative; RFU, relative fluorescent units.

    Techniques Used: Concentration Assay

    Treatment with 25 μM capsazepine significantly induces xCT expression by 24 and 48 hours relative to dimethyl sulfoxide (DMSO) treatment. Notes: These data are expressed as the fold change in xCT mRNA levels relative to DMSO ±standard error of mean and analyzed using a one-way analysis of variance (24 hours P <0.001, 48 hours P <0.05). * P <0.05; ** P <0.01.
    Figure Legend Snippet: Treatment with 25 μM capsazepine significantly induces xCT expression by 24 and 48 hours relative to dimethyl sulfoxide (DMSO) treatment. Notes: These data are expressed as the fold change in xCT mRNA levels relative to DMSO ±standard error of mean and analyzed using a one-way analysis of variance (24 hours P <0.001, 48 hours P <0.05). * P <0.05; ** P <0.01.

    Techniques Used: Expressing

    Dynamic Plantar Aesthesiometer (DPA) measurements of force required for withdrawal of the injected limb compared to the baseline results in capsazepine (CPZ)-treated and non-treated mice (100% on the y-axis is therefore equivalent to the animal’s behavior pre-tumor implantation surgery). A significant decrease in the force required to induce paw withdrawal relative to baseline is only seen in the vehicle-treated group beginning on day 27 as indicated by the asterisks. Both the 5 and 10 mg/kg CPZ-treated groups do not show any significant deviation from baseline measurements. A one-way analysis of variance (ANOVA) with a Dunnett post-test was used to show significant differences between time points relative to the baseline control. Paw withdrawal thresholds are increased in CPZ-treated mice increase in force required for paw withdrawal in the CPZ-treated mice relative to vehicle-treated mice (10 mg/kg) n=10; (5 mg/kg) n=11; (vehicle) n=13. One-way repeated measures ANOVA was used on the measurements past day 25 (marked by dotted line) showing significant differences between groups ( P <0.0001). While both doses were significantly different from vehicle mice ( P <0.05), differences between doses were not significant. Data are expressed as the mean required force as a percentage of the baseline score ±standard error of mean. * P <0.05; ** P <0.01; *** P <0.001.
    Figure Legend Snippet: Dynamic Plantar Aesthesiometer (DPA) measurements of force required for withdrawal of the injected limb compared to the baseline results in capsazepine (CPZ)-treated and non-treated mice (100% on the y-axis is therefore equivalent to the animal’s behavior pre-tumor implantation surgery). A significant decrease in the force required to induce paw withdrawal relative to baseline is only seen in the vehicle-treated group beginning on day 27 as indicated by the asterisks. Both the 5 and 10 mg/kg CPZ-treated groups do not show any significant deviation from baseline measurements. A one-way analysis of variance (ANOVA) with a Dunnett post-test was used to show significant differences between time points relative to the baseline control. Paw withdrawal thresholds are increased in CPZ-treated mice increase in force required for paw withdrawal in the CPZ-treated mice relative to vehicle-treated mice (10 mg/kg) n=10; (5 mg/kg) n=11; (vehicle) n=13. One-way repeated measures ANOVA was used on the measurements past day 25 (marked by dotted line) showing significant differences between groups ( P <0.0001). While both doses were significantly different from vehicle mice ( P <0.05), differences between doses were not significant. Data are expressed as the mean required force as a percentage of the baseline score ±standard error of mean. * P <0.05; ** P <0.01; *** P <0.001.

    Techniques Used: Injection, Tumor Implantation

    ( A ) Capsazepine (CPZ)-treated mice and non-treated mice. A significant decrease in weight applied to the tumor-bearing paw relative to baseline marked the onset of pain behavior in vehicle-treated mice on day 29 as indicated by the asterisks. This is delayed until day 36 for the 5 mg/kg CPZ-treated mice, and no significant changes from baseline are seen in the 10 mg/kg CPZ-treated group. A one-way analysis of variance (ANOVA) with a Dunnett post-test was used to show significant differences between time points relative to the baseline control. This graph shows a significant increase in weight distribution in the CPZ-treated mice, relative to vehicle-treated mice (10 mg/kg) n=10; (5 mg/kg) n=11; (vehicle) n=13. A one-way repeated measures ANOVA was used on the measurements past day 25 (marked by dotted line) showing significant differences between groups ( P =0.0008). While both doses were significantly different from vehicle mice ( P <0.05), differences between doses were not significant. Data are expressed as the mean weight bearing in the injected limb as a percentage of the baseline score ±SEM. ( B ) DWB measurements of time spent on the injected limb compared to the baseline results in CPZ-treated mice and non-treated mice. A decrease in the time spent on the tumor-bearing limb significantly deviates from baseline at day 32 with the CPZ-treated group not showing any deviation from baseline at any time point. Relative to the vehicle-treated group, an increase in time spent on injected limb is seen in the CPZ-treated mice (10 mg/kg) n=10; (5 mg/kg) n=11; (vehicle) n=13. A one-way repeated measures ANOVA was used on the measurements past day 25 (marked by dotted line) showing significant differences between groups ( P <0.005). While both doses were significantly different from vehicle mice ( P <0.05), differences between doses were not significant. Data are expressed as the mean time spent on the injected limb as a percentage of the baseline time ±SEM. * P <0.05; ** P <0.01; *** P <0.001.
    Figure Legend Snippet: ( A ) Capsazepine (CPZ)-treated mice and non-treated mice. A significant decrease in weight applied to the tumor-bearing paw relative to baseline marked the onset of pain behavior in vehicle-treated mice on day 29 as indicated by the asterisks. This is delayed until day 36 for the 5 mg/kg CPZ-treated mice, and no significant changes from baseline are seen in the 10 mg/kg CPZ-treated group. A one-way analysis of variance (ANOVA) with a Dunnett post-test was used to show significant differences between time points relative to the baseline control. This graph shows a significant increase in weight distribution in the CPZ-treated mice, relative to vehicle-treated mice (10 mg/kg) n=10; (5 mg/kg) n=11; (vehicle) n=13. A one-way repeated measures ANOVA was used on the measurements past day 25 (marked by dotted line) showing significant differences between groups ( P =0.0008). While both doses were significantly different from vehicle mice ( P <0.05), differences between doses were not significant. Data are expressed as the mean weight bearing in the injected limb as a percentage of the baseline score ±SEM. ( B ) DWB measurements of time spent on the injected limb compared to the baseline results in CPZ-treated mice and non-treated mice. A decrease in the time spent on the tumor-bearing limb significantly deviates from baseline at day 32 with the CPZ-treated group not showing any deviation from baseline at any time point. Relative to the vehicle-treated group, an increase in time spent on injected limb is seen in the CPZ-treated mice (10 mg/kg) n=10; (5 mg/kg) n=11; (vehicle) n=13. A one-way repeated measures ANOVA was used on the measurements past day 25 (marked by dotted line) showing significant differences between groups ( P <0.005). While both doses were significantly different from vehicle mice ( P <0.05), differences between doses were not significant. Data are expressed as the mean time spent on the injected limb as a percentage of the baseline time ±SEM. * P <0.05; ** P <0.01; *** P <0.001.

    Techniques Used: Injection

    capsazepine  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Alomone Labs capsazepine
    Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/capsazepine/product/Alomone Labs
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    capsazepine - by Bioz Stars, 2023-03
    91/100 stars

    Images

    capsazepine  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Alomone Labs capsazepine
    Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    capsazepine - by Bioz Stars, 2023-03
    86/100 stars

    Images

    capsazepine  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Alomone Labs capsazepine
    Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    capsazepine - by Bioz Stars, 2023-03
    86/100 stars

    Images

    cell treatments capsazepine  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Alomone Labs cell treatments capsazepine
    Cell Treatments Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell treatments capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cell treatments capsazepine - by Bioz Stars, 2023-03
    86/100 stars

    Images

    capsazepine  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Alomone Labs capsazepine
    Role of PKC/TRPV1 pathway in IL-1β-p53 interaction on glutamate synaptic transmission. A . Capsaicin, agonist of TRPV1 channels, caused a rapid and transient increase of sEPSC frequency in control conditions (p < 0.05) but not in slices pre-treated with PFT (p > 0.05). B . PKC activation with PMA was able to mimic IL-1β effects on sEPSC frequency in control slices, but not in presence of PFT. C . Nutlin, a p53 activator, enhances the IL-1β effects on sEPSC frequency (p < 0.05 respect to pre-drug value), but not in the presence of <t>capsazepine</t> (p > 0.05), TRPV1 channels antagonist, or chelerythrine (p > 0.05), PKC antagonist.
    Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    capsazepine - by Bioz Stars, 2023-03
    86/100 stars

    Images

    1) Product Images from "Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53"

    Article Title: Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53

    Journal: Molecular Neurodegeneration

    doi: 10.1186/1750-1326-9-56

    Role of PKC/TRPV1 pathway in IL-1β-p53 interaction on glutamate synaptic transmission. A . Capsaicin, agonist of TRPV1 channels, caused a rapid and transient increase of sEPSC frequency in control conditions (p < 0.05) but not in slices pre-treated with PFT (p > 0.05). B . PKC activation with PMA was able to mimic IL-1β effects on sEPSC frequency in control slices, but not in presence of PFT. C . Nutlin, a p53 activator, enhances the IL-1β effects on sEPSC frequency (p < 0.05 respect to pre-drug value), but not in the presence of capsazepine (p > 0.05), TRPV1 channels antagonist, or chelerythrine (p > 0.05), PKC antagonist.
    Figure Legend Snippet: Role of PKC/TRPV1 pathway in IL-1β-p53 interaction on glutamate synaptic transmission. A . Capsaicin, agonist of TRPV1 channels, caused a rapid and transient increase of sEPSC frequency in control conditions (p < 0.05) but not in slices pre-treated with PFT (p > 0.05). B . PKC activation with PMA was able to mimic IL-1β effects on sEPSC frequency in control slices, but not in presence of PFT. C . Nutlin, a p53 activator, enhances the IL-1β effects on sEPSC frequency (p < 0.05 respect to pre-drug value), but not in the presence of capsazepine (p > 0.05), TRPV1 channels antagonist, or chelerythrine (p > 0.05), PKC antagonist.

    Techniques Used: Transmission Assay, Activation Assay

    capsazepine  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Alomone Labs capsazepine
    Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    capsazepine - by Bioz Stars, 2023-03
    86/100 stars

    Images

    capsazepine  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Alomone Labs capsazepine
    Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    capsazepine - by Bioz Stars, 2023-03
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • capsazepine  (Alomone Labs)
    86
    Alomone Labs capsazepine
    Acid-induced prolonged antinociceptive signaling in muscle. The withdrawal responses of mouse hind paws to a 0.2-mN bending force in mice before and after intramuscular acid injection in the gastrocnemius muscle. (A) In the dual acid injection scheme, mice showed transient hyperalgesia after the first intramuscular acid injection and chronic hyperalgesia after a second acid injection spaced 5 days apart. (B) A mix of acid saline with APETx2 and <t>capsazepine</t> abolished the transient hyperalgesia with the first injection and prevented the development of chronic hyperalgesia induced by the second acid injection 5 days later. (C,D) With the first acid injection, acid induced a prolonged antinociceptive effect lasting for 2 days, with ASIC3 and TRPV1 blocked by APETx2 and capsazepine, respectively, and a second acid injection at day 2 could not induce any hyperalgesic effect. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine. *P < 0.05 compared with the response at baseline.
    Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    capsazepine - by Bioz Stars, 2023-03
    86/100 stars
    		  Buy from Supplier
    cell treatments capsazepine  (Alomone Labs)
    86
    Alomone Labs cell treatments capsazepine
    Acid-induced prolonged antinociceptive signaling in muscle. The withdrawal responses of mouse hind paws to a 0.2-mN bending force in mice before and after intramuscular acid injection in the gastrocnemius muscle. (A) In the dual acid injection scheme, mice showed transient hyperalgesia after the first intramuscular acid injection and chronic hyperalgesia after a second acid injection spaced 5 days apart. (B) A mix of acid saline with APETx2 and <t>capsazepine</t> abolished the transient hyperalgesia with the first injection and prevented the development of chronic hyperalgesia induced by the second acid injection 5 days later. (C,D) With the first acid injection, acid induced a prolonged antinociceptive effect lasting for 2 days, with ASIC3 and TRPV1 blocked by APETx2 and capsazepine, respectively, and a second acid injection at day 2 could not induce any hyperalgesic effect. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine. *P < 0.05 compared with the response at baseline.
    Cell Treatments Capsazepine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell treatments capsazepine/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cell treatments capsazepine - by Bioz Stars, 2023-03
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Acid-induced prolonged antinociceptive signaling in muscle. The withdrawal responses of mouse hind paws to a 0.2-mN bending force in mice before and after intramuscular acid injection in the gastrocnemius muscle. (A) In the dual acid injection scheme, mice showed transient hyperalgesia after the first intramuscular acid injection and chronic hyperalgesia after a second acid injection spaced 5 days apart. (B) A mix of acid saline with APETx2 and capsazepine abolished the transient hyperalgesia with the first injection and prevented the development of chronic hyperalgesia induced by the second acid injection 5 days later. (C,D) With the first acid injection, acid induced a prolonged antinociceptive effect lasting for 2 days, with ASIC3 and TRPV1 blocked by APETx2 and capsazepine, respectively, and a second acid injection at day 2 could not induce any hyperalgesic effect. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine. *P < 0.05 compared with the response at baseline.

    Journal: Molecular Pain

    Article Title: Acid mediates a prolonged antinociception via substance P signaling in acid-induced chronic widespread pain

    doi: 10.1186/1744-8069-10-30

    Figure Lengend Snippet: Acid-induced prolonged antinociceptive signaling in muscle. The withdrawal responses of mouse hind paws to a 0.2-mN bending force in mice before and after intramuscular acid injection in the gastrocnemius muscle. (A) In the dual acid injection scheme, mice showed transient hyperalgesia after the first intramuscular acid injection and chronic hyperalgesia after a second acid injection spaced 5 days apart. (B) A mix of acid saline with APETx2 and capsazepine abolished the transient hyperalgesia with the first injection and prevented the development of chronic hyperalgesia induced by the second acid injection 5 days later. (C,D) With the first acid injection, acid induced a prolonged antinociceptive effect lasting for 2 days, with ASIC3 and TRPV1 blocked by APETx2 and capsazepine, respectively, and a second acid injection at day 2 could not induce any hyperalgesic effect. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine. *P < 0.05 compared with the response at baseline.

    Article Snippet: Briefly, mice received an intramuscular injection in the gastrocnemius muscle of acid containing 20 μL acid saline (pH 4.0) with or without APETx2 (20 pmol; Alomone, Jerusalem, Israel) and capsazepine (1 nmol; Torcis, Avonmouth, UK).

    Techniques: Injection

    Substance P mediates the acid-induced prolonged antinociception in acid-induced chronic widespread pain model. (A,B) APETx2 and capsazepine prevented acid-induced chronic hyperalgesia in tachykinin 1-positive ( Tac1 +/+ ) mice (A) but not Tac1 −/− mice (B) when the second acid injection was given the next day. (C) Pretreatment with pH 7.4 saline did not affect the acid-induced hyperalgesia in wild-type mice. (D) Pretreatment with SM-SP abolished the acid-induced transient hyperalgesia the next day and prevented the development of chronic hyperalgesia induced by a second acid injection 5 days later. (E) Pretreatment with SM-SP 5 days before the acid injection did not affect the acid-induced transient and chronic hyperalgesia in the dual acid injection scheme. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. Green arrow indicates when mice received a pretreatment of pH 7.4 saline 1 day before the acid injection. Blue arrows indicate when mice received a pretreatment of SM-SP 1 or 5 days before acid injection. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine; SM-SP, [Sar 9 ,Met(O 2 ) 11 ]-substance P; Tac1, tachykinin 1. *P < 0.05 compared with the response at baseline.

    Journal: Molecular Pain

    Article Title: Acid mediates a prolonged antinociception via substance P signaling in acid-induced chronic widespread pain

    doi: 10.1186/1744-8069-10-30

    Figure Lengend Snippet: Substance P mediates the acid-induced prolonged antinociception in acid-induced chronic widespread pain model. (A,B) APETx2 and capsazepine prevented acid-induced chronic hyperalgesia in tachykinin 1-positive ( Tac1 +/+ ) mice (A) but not Tac1 −/− mice (B) when the second acid injection was given the next day. (C) Pretreatment with pH 7.4 saline did not affect the acid-induced hyperalgesia in wild-type mice. (D) Pretreatment with SM-SP abolished the acid-induced transient hyperalgesia the next day and prevented the development of chronic hyperalgesia induced by a second acid injection 5 days later. (E) Pretreatment with SM-SP 5 days before the acid injection did not affect the acid-induced transient and chronic hyperalgesia in the dual acid injection scheme. Black arrows indicate when mice received the intramuscular acid injection. Red arrows indicate when mice received the co-injection of acid with APETx2 and capsazepine. Green arrow indicates when mice received a pretreatment of pH 7.4 saline 1 day before the acid injection. Blue arrows indicate when mice received a pretreatment of SM-SP 1 or 5 days before acid injection. B, baseline on day 0; D, day; WT, wild-type mice; CZP, capsazepine; SM-SP, [Sar 9 ,Met(O 2 ) 11 ]-substance P; Tac1, tachykinin 1. *P < 0.05 compared with the response at baseline.

    Article Snippet: Briefly, mice received an intramuscular injection in the gastrocnemius muscle of acid containing 20 μL acid saline (pH 4.0) with or without APETx2 (20 pmol; Alomone, Jerusalem, Israel) and capsazepine (1 nmol; Torcis, Avonmouth, UK).

    Techniques: Injection